Shots:

• The US FDA has accepted sNDA and granted PR for Brilinta to reduce subsequent stroke in patients experiencing an acute ischemic stroke or TIA. The sNDA is based on P-III THALES study assessing Brilinta (90mg- bid- for 30 days) + aspirin vs aspirin as monothx. in 11-000 patients with non-cardioembolic acute ischaemic stroke or high-risk TIA
• The study resulted in a reduction in the risk of the primary composite endpoint of stroke and death while the safety is consistent with the known profile of the therapy. The anticipated PDUFA date is in Q4’20
• Brilinta (ticagrelor) is an oral- reversible- direct-acting P2Y12 receptor antagonist acts by inhibiting platelet activation. The therapy when co-administered with aspirin prevents atherothrombotic events in adult patients with ACS- or for patients with a history of MI and a high risk of developing an atherothrombotic event

Click here to read full press release/ article 

 Ref: AstraZeneca | Image: New York Post